Fig. 3

The combination of HVEM-Fc and PD-1 inhibitor decreased the tumor growth and extended the survival of C57BL6 and KP mice. Notes: A-B The treatment effects were more pronounced in the drug combination group in subcutaneous tumor-bearing mouse model; C-E The treatment effects were more pronounced in the drug combination group in tail vein tumor-bearing mouse model; F-G No obvious drug associated damage was observed in the drug combination group; H The scores of NK cells, CD4 T and CD8 T cells; I The drug combination effectively prolonged the survival of genetically engineered mouse models; J-L Ki67 index, HE of pulmonary tissues and dry lung weight confirmed our results; M Subsequent tumor challenge was effectively controlled by a robust and rapid immunological memory T cell response elicited by prior HVEM-Fc treatment; N–O The immune cells depletion antibodies were used. The image captured at 200 × magnification